Tom Greenhalgh, Author at Psychiatry Advisor

Examining Postpartum Depression Amid COVID-19

By

Tom Greenhalgh

June 7, 2022

The COVID-19 pandemic has led to overwhelmed hospitals, economic hardships, and mortality on a large scale. Amidst all of this, was there an effect on pregnancies and postpartum depression?

Depressive Disorder

Gout and Depression: Is There a Link?

By

Tom Greenhalgh

December 19, 2019

In recent years, researchers have investigated a potential link between gout and depression. We review clinical evidence on the subject.

Depressive Disorder

Avoid Sweets to Stave Off the Holiday Blues, Study Says

By

Tom Greenhalgh

December 18, 2019

People who are prone to depression might want to pass up on the sweets this holiday season, according to a new study.

Depressive Disorder

We Surveyed HCPs About CBD: 6 Key Takeaways

By

Tom Greenhalgh

November 5, 2019

We surveyed HCPs about CBD to find out if and how the phytocannabinoid is affecting practices across America.

Schizophrenia and Psychoses

Researchers Evaluate Smartphone Intervention for Schizophrenia Spectrum Disorders

By

Tom Greenhalgh

October 25, 2019

Researchers evaluated a smartphone intervention designed to manage lingering symptoms in schizophrenia spectrum disorders.

A prescription bottle of pills spilled over

Addiction

Opioid Epidemic: Is Overdose More Likely if a Family Member Has a Prescription?

By

Tom Greenhalgh

October 7, 2019

Investigators examined whether opioid overdose is more likely if a family member has a prescription. We review their findings.

Ketamine, an anesthetic long known as a psychedelic and addictive street drug, has shown efficacy in treating individuals with depression that does not respond to standard treatments. In fact, certain academic medical centers offer ketamine infusions to patients with severe depression, and pharmaceutical companies are working on developing antidepressants inspired by the drug.1 Yet, while ketamine offers promise of a significant breakthrough in solving treatment-resistant depression, it remains a challenge for clinicians who are wary of the potential for abuse and dependence.2

Depression Advisor

Ketamine for Depression: Clinical Evidence and Concerns

By

Tom Greenhalgh

July 12, 2019

Ketamine is gaining ground as a promising option for treatment-resistant depression, but not every clinician is buying in. We review clinical evidence and concerns surrounding the drug.